Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

RISANKIZUMAB vs RISPERIDONE: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

RISANKIZUMAB vs RISPERIDONE: Safety Overview

Metric RISANKIZUMAB RISPERIDONE
Total FAERS Reports 2,642 79,288
Deaths Reported 41 4,120
Death Rate 1.6% 5.2%
Hospitalizations 439 18,771
Average Patient Age 52.1 yrs 31.9 yrs
% Female Patients 51.3% 15.6%
FDA Approval Date N/A Apr 12, 2007
Manufacturer AbbVie Inc. NuCare Pharmaceuticals, Inc.
Route SUBCUTANEOUS ORAL
Marketing Status N/A Prescription